Trial Profile
A Multicenter, Randomized, Double-blind, Long-term Extension Study to Determine the Safety, Tolerability, and Preliminary Efficacy of CCI-779 in Subjects With Relapsing Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Aug 2014
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 12 Oct 2007 Status changed from in progress to completed.
- 20 Nov 2005 New trial record.